A Phase 1b Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (P13K/mTOR Inhibitor) In Combination With Other Anti-Tumor Agents
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs Gedatolisib (Primary) ; Cisplatin; Dacomitinib; Docetaxel
- Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 16 Oct 2019 Planned End Date changed from 18 Oct 2019 to 10 Jan 2020.
- 16 Oct 2019 Planned primary completion date changed from 18 Oct 2019 to 10 Jan 2020.
- 22 Dec 2018 Planned End Date changed from 1 Jan 2019 to 18 Oct 2019.